Related Experiment Video
Updated: Mar 15, 2026
05:19
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
1.0K
Hypofractionated radiotherapy for localized prostate cancer.
Stefan Höcht1, Daniel M Aebersold2, Clemens Albrecht3
1Radiologie, Nuklearmedizin und Strahlentherapie, Xcare Gruppe, Saarlouis, Germany. stefan.hoecht@googlemail.com.
Summary
Moderate hypofractionated radiotherapy for prostate cancer shows potential but requires caution in routine use. Extreme hypofractionation is currently limited to clinical trials due to insufficient long-term data.
Area of Science:
- Radiation Oncology
- Urologic Oncology
Background:
- Hypofractionated radiotherapy is an evolving treatment for prostate cancer.
- Assessing its routine applicability requires evaluation of long-term outcomes and toxicity.
Purpose of the Study:
- To provide an overview of the current status of hypofractionated radiotherapy for prostate cancer.
- To focus on the applicability of these techniques in routine clinical practice.
Main Methods:
- Systematic review of recent large-scale trials on moderate and extreme hypofractionation.
- Expert panel assessment of outcome parameters, including long-term toxicity and disease control.
- Evaluation of available data from prospective trials and phase 3 studies.
Main Results:
- Moderate hypofractionation (2.4-3.4 Gy/fraction) suggests equivalent outcomes but may increase short- and long-term toxicity.
- Large phase 3 trials for extreme hypofractionation (>4.0 Gy/fraction) are lacking.
- Limited prospective trials offer follow-up exceeding 2-3 years.
Conclusions:
- Moderate hypofractionation should be used cautiously in routine practice, adhering to quality standards and evidence-based regimens.
- Extreme hypofractionation should be reserved for prospective clinical trials until robust long-term data are available.
